Pentacel Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to global implementation of childhood immunization schedules, established efficacy of combination vaccines, public health vaccination initiatives, availability through hospitals and clinics, strong regulatory support for pediatric vaccines.

The growth in the forecast period can be attributed to expansion of universal immunization programs, increasing focus on vaccine coverage in emerging markets, improvements in vaccine manufacturing efficiency, growing public health investments, enhanced surveillance of preventable diseases. Major trends in the forecast period include growing adoption of combination pediatric vaccines, emphasis on reducing injection burden, expansion of routine immunization programs, improved cold-chain vaccine distribution, focus on vaccination compliance and coverage.

The increasing prevalence of tetanus is expected to drive the growth of the Pentacel market. The rise in tetanus cases is primarily attributed to insufficient immunization coverage, inadequate wound care, and limited access to healthcare in rural or underserved areas. Pentacel helps prevent tetanus by providing vaccination against the tetanus toxin through its combination of diphtheria, tetanus, and pertussis (DTaP) components, stimulating the immune system to produce protective antibodies. For example, in 2023, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported approximately 21,830 cases of tetanus globally, a significant increase from 6,705 cases in 2022. As a result, the growing prevalence of tetanus is driving the growth of the Pentacel market.

The rising demand for combination vaccines is expected to drive the growth of the Pentacel market. Combination vaccines combine multiple vaccine components into a single shot, offering protection against several diseases simultaneously. The demand for these vaccines is increasing due to their ability to reduce the number of injections required, improve vaccination compliance, and provide more convenient and cost-effective immunization options. Pentacel is a combination vaccine that provides protection against five diseases, including diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae type b (Hib), in a single shot, reducing the number of injections needed for children and improving vaccination compliance. For example, in September 2023, the National Health Service (NHS), a UK-based publicly funded healthcare system, reported that 88.7% of children in England received the combined Hib/MenC vaccine during 2022-23. As a result, the growing demand for combination vaccines is contributing to the expansion of the Pentacel market.

The increasing birth rates are also expected to accelerate the growth of the Pentacel market. The rise in birth rates can be attributed to various factors, including improved healthcare, government incentives, and shifting societal attitudes. Pentacel is a combination vaccine used in newborns and young children to protect against diphtheria, tetanus, pertussis (whooping cough), poliovirus, and Haemophilus influenzae type b (Hib). It reduces the number of injections required, ensuring efficient and early immunization against these serious diseases. For instance, in October 2024, the Australian Bureau of Statistics, a government agency in Australia, reported that 24,737 Aboriginal and Torres Strait Islander births were registered in 2023, an increase of 349 babies from 2022. Therefore, the rising birth rates are contributing to the growth of the Pentacel market.

Major companies operating in the pentacel market are Sanofi Pasteur.

North America was the largest region in the Pentacel market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pentacel market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pentacel market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are affecting the Pentacel market by increasing costs of imported vaccine components, biologic raw materials, sterile packaging, and cold-chain logistics equipment required for vaccine distribution. Public immunization programs in North America and Europe are most impacted due to reliance on global vaccine supply chains, while developing regions face pricing sensitivity. These tariffs can increase procurement costs and strain public health budgets. However, they are also encouraging domestic vaccine manufacturing, regional fill-finish capacity expansion, and long-term resilience in pediatric vaccine supply chains.

The pentacel market research report is one of a series of new reports that provides pentacel market statistics, including pentacel industry global market size, regional shares, competitors with a pentacel market share, detailed pentacel market segments, market trends and opportunities, and any further data you may need to thrive in the pentacel industry. This pentacel market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pentacel is a combination vaccine that protects against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b (Hib). It is administered in a four-dose series to children aged 6 weeks to 4 years as part of routine immunization schedules. Pentacel helps reduce the need for multiple injections, improving vaccination compliance and convenience.

The primary formulations in the Pentacel market are the liquid vaccine and the lyophilized vaccine. The Pentacel liquid vaccine is a combination vaccine in which one of the components, the DTaP-IPV vaccine, is provided in liquid form. The vaccine targets several diseases, including diphtheria, tetanus, pertussis (whooping cough), poliomyelitis, and invasive disease caused by Haemophilus influenzae type b (Hib). The various end users of Pentacel include healthcare providers, hospitals, and public health programs.

The pentacel market consists of sales of combination vaccines, vaccine components, and ancillary products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.